Navigation Links
Benefit of cancer prevention surgery differs between women with BRCA1 and BRCA2 mutations

The surgical removal of the ovaries has been widely adopted as a cancer-risk-reducing strategy for women with either BRCA1 or BRCA2 mutations. A new multicenter study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) is the first prospective examination of the impact of this procedure in which BRCA2 mutation carriers were analyzed separately from BRCA1 mutation carriers. All previous studies evaluating this approach have only examined BRCA1 and BRCA2 mutation carriers together or have limited their analysis to BRCA1 mutation carriers alone.

The findings of the new study, to be published in the March 2008 issue of the Journal of Clinical Oncology, may have important implications for women comparing the risks and benefits of specific cancer-risk-reduction options.

According to the research, the surgery called risk-reducing salpingo-oophorectomy (RRSO) may confer different benefits for women at inherited risk for breast and ovarian cancer depending upon whether BRCA1 or BRCA2 is abnormal. The efficacy of this procedure for the prevention of breast and gynecologic cancer had never been evaluated in groups of women stratified according to mutation type, despite 17 percent to 39 percent of all BRCA mutation carriers having a mutation in the BRCA2 gene.

These findings will allow doctors to better tailor risk-reduction approaches for women at inherited risk for breast and ovarian cancer, said the studys lead author, Noah Kauff, MD, a gynecologist and geneticist at MSKCC. Given these results, further studies evaluating the efficacy of risk-reduction strategies in BRCA mutation carriers will likely need to stratify by the specific gene mutated, he added.

Researchers compared the incidence of breast and gynecologic cancers between a group of 509 women 30 years of age or older who carried a BRCA1 or BRCA2 mutation and had undergone RRSO, and a group of 283 women with these mutations who did not have the surgery. The women were followed prospectively for three years via questionnaire and medical record review.

Investigators found that RRSO was associated with a 72 percent breast cancer risk reduction in women with BRCA2 mutations nearly twice the reduction in breast cancer risk compared to women with BRCA1 mutations. The surgery also reduced the risk of gynecologic cancer by 85 percent in women with a BRCA1 mutation. While protection against gynecologic cancer was suggested in women with a BRCA2 mutation, researchers were not able to estimate the level of reduced risk due to the low incidence of gynecologic cancers among women with these mutations.

Further analyses demonstrated that RRSO appeared to reduce the risk of estrogen receptor (ER)-positive breast cancer by 78 percent in women with a mutation in either BRCA1 or BRCA2, but had no effect on the development of ER-negative breast cancers. Because BRCA1 carriers are more likely to be diagnosed with ER-negative breast cancers, the authors note that carriers of these mutations need to consider additional breast-cancer-risk-reduction strategies, such as intensive screening with breast MRI or prophylactic mastectomy.

While our results suggest that removal of the ovaries in women with BRCA1 or BRCA2 mutations is highly protective against ER-positive breast cancers, further research is urgently needed to develop effective non-surgical prevention strategies for the ER-negative cancers that are frequently associated with these mutations, said Dr. Kauff.


Contact: Esther Napolitano
Memorial Sloan-Kettering Cancer Center

Related medicine news :

1. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
2. Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia
3. Discovery of sugar sensor in intestine could benefit diabetes
4. Study shines more light on benefit of vitamin D in fighting cancer
5. Vitamin Es lack of heart benefit linked to dosage
6. Practice-based intervention has sustained benefits for children and families
7. Manic phase of bipolar disorder benefits from breast cancer medication
8. Medicare Prescription Drug Benefit, Nonprofit Hospitals, Ambulatory Surgery Centers, Statistical Methods, and Pay-For-Performance Highlighted In the Latest INQUIRY Journal
9. Scientists highlight benefits of genetic research in sport, but warn of ethical concerns
10. The Butterfly Ball to Benefit Lung Association
11. Smaller breast reduction surgeries provide health benefits and should be reimbursed
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... ... at the Radiology Society of North America (RSNA) annual meeting, being held November ... growth from 2014. Throughout 2015, the company has completed installations for Integrated ...
(Date:11/30/2015)... ... November 30, 2015 , ... Holcomb – ... leading plastic surgery practices in Florida, is proud to announce that Dr. Joshua ... innovations giant Ethicon Inc., a Johnson & Johnson Company. , Ethicon is a ...
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra ... TIGR® Matrix Surgical Mesh technology for soft tissue repair in the US via ... a long-term resorbable surgical mesh intended to support and reinforce soft tissue for ...
(Date:11/30/2015)... ... ... TransPack Volume 6 features 30 customizable transitions created exclusively for use within ... with blur & drop shadow options. Utilize the controls in the inspector window ... the next with TransPack's easily customizable styles. , TransPack Volume 6 features ...
(Date:11/30/2015)... ... November 30, 2015 , ... Workstation ... more than 30 HealthPostures’ dealers located throughout the United States, is OneStop Ergonomics. ... of corporate, industrial, manufacturing and government workers and organizational leaders that are introduced ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015  Novartis will demonstrate the strength ... th American Society of Hematology (ASH) Annual Meeting. ... as well as supportive care, including key findings in ... cell therapies. The ASH Annual Meeting will be held ... Novartis Oncology . "We will be presenting ...
(Date:11/30/2015)... BOSTON , November 30, 2015 ... medicines directed at up to 10 G protein-coupled receptor ... PFE ) to research and develop potential new medicines ... targets across multiple therapeutic areas. --> Heptares ... development company and wholly-owned subsidiary of Sosei Group Corporation ...
(Date:11/30/2015)... TEL AVIV, Israel , November 30, 2015 /PRNewswire/ ... EMITF ) ("Elbit" or the "Company") announced today that it ... Ministry of Food and Drug Safety (MFDS) has approved ... behavioral disorders. --> --> ... presenting a non-invasive treatment alternative that combines two technologies: ...
Breaking Medicine Technology: